Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more
Hangzhou AGS MedTech Co. Ltd. A (688581) - Total Liabilities
Latest total liabilities as of June 2025: CN¥219.33 Million CNY
Based on the latest financial reports, Hangzhou AGS MedTech Co. Ltd. A (688581) has total liabilities worth CN¥219.33 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hangzhou AGS MedTech Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hangzhou AGS MedTech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Hangzhou AGS MedTech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou K-Hiragawa Electronic Technology Co. Ltd. A
SHG:603052
|
China | CN¥535.12 Million |
|
Canaccord Genuity Group Inc
PINK:CCORF
|
USA | $6.25 Billion |
|
Tes Touch Embedded Solutions
SHE:003019
|
China | CN¥1.11 Billion |
|
Shengyuan Environmental Protection
SHE:300867
|
China | CN¥5.02 Billion |
|
Energy Absolute Public Company Limited
BK:EA
|
Thailand | ฿56.86 Billion |
|
Diamond Hill Investment Group Inc
NASDAQ:DHIL
|
USA | $83.97 Million |
|
Nam Long Investment Corp
VN:NLG
|
Vietnam | ₫14.00 Trillion |
|
Natural Gas Services Group Inc
NYSE:NGS
|
USA | $290.89 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Hangzhou AGS MedTech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou AGS MedTech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou AGS MedTech Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥152.67 Million | +24.29% |
| 2023-12-31 | CN¥122.83 Million | +34.11% |
| 2022-12-31 | CN¥91.59 Million | +29.83% |
| 2021-12-31 | CN¥70.55 Million | -- |